🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for First in Man Study to Evaluate Initial Safety

CS-121 APOC3 Base Editing in FCS NCT07176923EARLY Phase 11 site📍 Hefei CorrectSequence Therapeutics Co., Ltd · Tests: CS-121 A First-in-Human Single and Multiple Ascending Dose Study of MT-201 NCT07219368Phase 11 site📍 San Diego Mirador Therapeutics, Inc. · Tests: MT-201, Placebo A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors NCT06926283Phase 14 sites📍 Changsha📍 Hangzhou📍 Beijing Hangzhou DAC Biotechnology Co., Ltd. · Tests: DXC008 A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) NCT06452277Phase 3279 sites📍 Newport Beach📍 San Diego📍 San Francisco Bayer · Tests: Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors NCT06026410Phase 138 sites📍 Phoenix📍 Tucson📍 Los Angeles Kura Oncology, Inc. · Tests: Darlifarnib, Cabozantinib, Adagrasib Study of FID-022 in Participants With Advanced Solid Tumors NCT06694480Phase 13 sites📍 Duarte📍 Los Angeles📍 Tampa Fulgent Pharma LLC. · Tests: FID-022 A Study in Patients With Metastatic Castration-Resistant Prostate Cancer NCT07719361Phase 110 sites📍 Los Angeles📍 Boston📍 Boston Flare Therapeutics Inc. · Tests: FX-111 First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics NCT07169318Phase 11 site📍 Overland Park National Institute of Allergy and Infectious Diseases (NIAI… · Tests: Placebo for VNT-101, VNT-101 A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours NCT06868199Phase 1, Phase 26 sites📍 Ryde📍 Ryde📍 Wollongong LaNova Medicines Limited · Tests: LM-168, Toripalimab A First in Human Study of PLT012 in Participants With Solid Tumor Cancers NCT07337525Phase 14 sites📍 Los Angeles📍 Dallas📍 Houston Pilatus Biosciences Inc · Tests: PLT012 A Study of PYX-201 in Advanced Solid Tumors NCT05720117Phase 129 sites📍 Scottsdale📍 Los Angeles📍 Denver Pyxis Oncology, Inc · Tests: PYX-201 A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma NCT06630806Phase 119 sites📍 Phoenix📍 Jacksonville📍 Rochester Sanofi · Tests: SAR446523 An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors NCT07359066Phase 1, Phase 22 sites📍 Beijing📍 Harbin Shanghai SciBrunch Therapeutics Co., Ltd. · Tests: SRP1020 A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1106 in Advanced Solid Tumors NCT05650242Phase 11 site📍 Beijing Shandong Boan Biotechnology Co., Ltd · Tests: BA1106 First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma NCT06797999Phase 1, Phase 29 sites📍 Aurora📍 Miami📍 New York Adcendo ApS · Tests: Antibody-drug conjugate (ADC) Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors NCT06384352Phase 121 sites📍 Aurora📍 Denver📍 North Haven MediLink Therapeutics (Suzhou) Co., Ltd. · Tests: YL211, YL211+Pembrolizumab, YL211 + Pembro or Pembro+ Pemetrexed + (Carboplatin or Cisplatin) mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults NCT07557602Phase 12 sites📍 Herston📍 Melbourne Vaccine Company, Inc, a wholly owned subsidiary of Eli Lill… · Tests: VXCO-102, Placebo A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults NCT07540910Phase 11 site📍 San Antonio Enanta Pharmaceuticals, Inc · Tests: EDP-978, Placebo A First-in-Human Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of a Novel CRISPR RNA-editing Therapy in Patients with Mecp2 Duplication Syndrome, a Rare Orphan Disease (HERO) NCT06615206NA1 site📍 Beijing HuidaGene Therapeutics Co., Ltd. · Tests: HG204 First in Human Study of YB1-X7 Injection NCT06889675NA1 site📍 Langfang Shanghai Salvectors Biotechnology LTD. · Tests: YB1-X7 Injection (IT), YB1-X7 Injection (IV), PD-1 inhibitor A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors NCT05954312Phase 126 sites📍 Jacksonville📍 Sarasota📍 Tampa Vividion Therapeutics, Inc. · Tests: VVD-130037, Docetaxel, Paclitaxel, Pembrolizumab Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma NCT04879043Phase 1, Phase 224 sites📍 Atlanta📍 Louisville📍 Omaha Heidelberg Pharma AG · Tests: HDP-101 A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors NCT06258408Phase 12 sites📍 Guangzhou📍 Zhengzhou Broadenbio Ltd., Co. · Tests: BB102 tablet A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors NCT06914128Phase 1, Phase 263 sites📍 Birmingham📍 Duarte📍 Los Angeles Bayer · Tests: BAY 3713372 GenSci143 in Participants With Advanced Solid Tumors NCT07252414Phase 19 sites📍 Zhengzhou📍 Wuhan📍 Changsha Changchun GeneScience Pharmaceutical Co., Ltd. · Tests: GenSci143 for injection IDOV-Immune for Advanced Solid Tumors NCT06910657Phase 15 sites📍 St Louis📍 Houston📍 San Antonio ViroMissile, Inc. · Tests: IDOV-Immune (oncolytic vaccinia virus) A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1) NCT06942572Phase 1, Phase 25 sites📍 Aurora📍 Miami📍 Boston Splice Bio · Tests: SB-007 A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B NCT07389044Phase 15 sites📍 Hong Kong📍 Hong Kong📍 Chisinau IntegerBio · Tests: IB-001, Placebo, Peginterferon Alfa-2A A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors NCT06253130Phase 1, Phase 257 sites📍 Tucson📍 Little Rock📍 Irvine Eikon Therapeutics · Tests: IMP1734 A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors. NCT07778498Phase 1, Phase 29 sites📍 Los Angeles📍 Orlando📍 Lake Success Phrontline Biopharma · Tests: TJ102
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy